Edgewise Therapeutics, Inc. EWTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$176.01M-20.5% | -$167.8M-25.4% | -$157.24M-26.5% | -$150.7M-30.1% | -$146.09M-38.0% | ||
| $2.06M-1.3% | $2.04M-0.6% | $2.09M+6.9% | $2.09M+12.6% | $2.09M+19.0% | ||
| $34.41M+19.1% | $34.75M+40.6% | $32.61M+47.4% | $31.41M+58.6% | $28.9M+55.4% | ||
| -$148.49M-25.5% | -$143.82M-31.9% | -$132.18M-21.4% | -$124.78M-20.5% | -$118.3M-21.1% | ||
| $472K-55.4% | $256K-80.5% | $457K-61.9% | $872K-23.2% | $1.06M-36.7% | ||
| —— | —— | —— | —— | —— | ||
| $206.04M+1,881% | $196.09M-21.3% | $195.01M-34.9% | $196.68M-33.6% | $10.4M-96.5% | ||
| —— | —— | —— | —— | —— | ||
| -$148.97M-24.8% | -$144.07M-30.6% | -$132.64M-20.5% | -$125.65M-20.0% | -$119.36M-20.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Edgewise Therapeutics, Inc. generate?
- Edgewise Therapeutics, Inc. (EWTX) generated -$148.5M in operating cash flow over the trailing twelve months.
- What is Edgewise Therapeutics, Inc.'s free cash flow?
- After $472.0K of capital expenditures, Edgewise Therapeutics, Inc.'s free cash flow was -$149.0M over the trailing twelve months, down 24.8% year over year.
- Where does Edgewise Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.